前列腺素E1恢复系统性硬化症患者内皮祖细胞功能
研究纳入12例伴雷诺现象的系统性硬化症患者和5名健康对照,评估静脉给予前列腺素E1(8-9天)前后集落形成单位内皮细胞(CFU-EC)和内皮集落形成细胞(ECFC)簇数变化。结果显示患者基线CFU-EC和ECFC簇数显著低于健康对照(P=0.02和P<0.01),治疗后两者均显著增加(P=0.02和P=0.001),达到与健康对照相当水平。
要点
- 系统性硬化症患者基线CFU-EC和ECFC簇数显著低于健康对照(P=0.02和P<0.01)。
- 静脉前列腺素E1治疗8-9天后,患者CFU-EC和ECFC簇数显著增加(P=0.02和P=0.001)。
- 治疗后患者CFU-EC和ECFC簇数达到与健康对照相当水平,健康对照两时间点无显著变化。
核心结论
- 前列腺素E1治疗恢复系统性硬化症患者CFU-EC和ECFC水平,提示其可能在修复血管损伤中发挥作用。
- 这些发现突出前列腺素E1超越血管扩张的治疗益处,支持其用于系统性硬化症相关微血管病。
研究设计与样本
- 研究评估前列腺素E1对12例伴雷诺现象的系统性硬化症患者和5名健康对照内皮祖细胞水平的影响。
- 采用标准化培养方法在治疗前后定量CFU-EC和ECFC簇,前列腺素E1静脉给药8-9天。
主要发现
- 系统性硬化症患者基线CFU-EC和ECFC簇数显著低于健康对照(P=0.02和P<0.01)。
- 前列腺素E1治疗后,系统性硬化症患者CFU-EC和ECFC簇数显著增加(P=0.02和P=0.001),达到与健康对照相当水平。
- 健康对照在两个时间点未观察到显著变化。
- 系统性硬化症患者与健康对照间簇数变化值(delta)存在显著差异(CFU-EC:P=0.03;ECFC:P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is a chronic autoimmune disease characterized by microvascular injury and impaired angiogenesis, with endothelial progenitor cells (EPCs) playing a key role in vascular repair. EPC subsets, including endothelial colony-forming cells (ECFCs) and colony-forming unit-endothelial cells (CFU-ECs), are known to be dysfunctional in SSc, contributing to disease-associated vasculopathy. Prostaglandin E1 (PGE1) is a vasodilator with potential pro-angiogenic effects, but its impact on EPC numbers and function in SSc remains unexplored. This study aimed to investigate whether PGE1 treatment can modulate EPC numbers, specifically CFU-ECs and ECFCs, in patients with SSc and RP, and evaluate its potential role in promoting vascular repair. METHODS: This study evaluated the effect of PGE1 on EPC levels in 12 SSc patients with RP and five healthy controls (HCs). CFU-EC and ECFC clusters were quantified before and after PGE1 treatment using standardized culture methods. PGE1 was administered intravenously over 8-9 days. Statistical analyses compared EPC counts between the groups and time points. RESULTS: Baseline CFU-EC and ECFC cluster counts were significantly reduced in SSc patients compared with HCs (P = 0.02 and P < 0.01, respectively). Following PGE1 treatment, both CFU-EC and ECFC clusters significantly increased in SSc patients (P = 0.02 and P = 0.001, respectively), reaching levels comparable to HCs. No significant changes were observed in HCs across two time points. A significant delta in cluster counts was observed in SSc patients vs. HCs (CFU-EC: P = 0.03; ECFC: P = 0.01). CONCLUSION: PGE1 treatment restores CFU-EC and ECFC levels in SSc patients, suggesting a potential role in repairing vascular damage. These findings highlight PGE1's therapeutic benefits beyond vasodilation, supporting its use in SSc-associated microvasculopathy.
引用
- Potjewijd J, Tobal R, Arends SJ, et al. Prostaglandin E1 restores endothelial progenitor cell function in systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 40131427. doi:10.1093/rheumatology/keaf174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。